Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE...
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of...
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.84 | -17.8343949045 | 4.71 | 4.8 | 3.78 | 3647 | 4.28431564 | CS |
| 4 | -1.08 | -21.8181818182 | 4.95 | 5.2 | 3.78 | 2083 | 4.52541813 | CS |
| 12 | -1.23 | -24.1176470588 | 5.1 | 5.85 | 3.78 | 1592 | 4.87526919 | CS |
| 26 | -4.53 | -53.9285714286 | 8.4 | 9 | 3.78 | 1708 | 5.29941292 | CS |
| 52 | -4.53 | -53.9285714286 | 8.4 | 9 | 3.78 | 1708 | 5.29941292 | CS |
| 156 | -4.53 | -53.9285714286 | 8.4 | 9 | 3.78 | 1708 | 5.29941292 | CS |
| 260 | -4.53 | -53.9285714286 | 8.4 | 9 | 3.78 | 1708 | 5.29941292 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
